| Zosano Pharma (ZSAN) | |||
|---|---|---|---|
| 0.5576 0 (0%) | 12-31 19:00 | ||
| Open: | 0.5188 | Pre. Close: | 0.5576 |
| High: | 0.635 | Low: | 0.46 |
| Volume: | 1,155,058 | Market Cap: | 0(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 0.74 One year: 0.87 |
| Support: | Support1: 0.53 Support2: 0.46 |
| Resistance: | Resistance1: 0.63 Resistance2: 0.74 |
| Pivot: | 0.56 |
| Moving Averages: | MA(5): 0.56 MA(20): 0.56 MA(100): 0.48  MA(250): 0.79  |
| MACD: | MACD(12,26): Signal(12,26,9): |
| %K %D: | %K(14,3): 55.77 %D(3): 55.77 |
| RSI: | RSI(14): 64.44 |
| 52-Week: | High: 7.630114 Low: 0.1129 Change(%): -7.5 |
| Average Vol(K): | 3-Month: 1155 10-Days: 1155 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 0.631 - 0.635 | 0.635 - 0.637 |
| Low: | 0.454 - 0.457 | 0.457 - 0.459 |
| Close: | 0.555 - 0.56 | 0.56 - 0.565 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ZSAN ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 105 bars. This is a sign that the market may be about to initiate a new trend. |
| Company profile |
|---|
| Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Capital Market | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | |
| Shares Float (M) | 4.90 |
| % Held by Insiders | 4630000.00 |
| % Held by Institutions | 5.47 |
| Shares Short (K) | 370 |
| Shares Short Prior Month (K) | |
| Stock Financials | |
|---|---|
| EPS | -29300000.000 |
| Book Value (p.s.) | |
| Profit Margin | |
| Operating Margin | -4.00 |
| Return on Assets (ttm) | 683.0 |
| Return on Equity (ttm) | -41.9 |
| Qtrly Rev. Growth | 659000.0 |
| Gross Profit (p.s.) | -14.833 |
| Sales Per Share | -58.650 |
| EBITDA (p.s.) | -6376900.000 |
| Qtrly Earnings Growth | -15.69 |
| Operating Cash Flow (M) | |
| Levered Free Cash Flow (M) | -28.67 |
| Stock Valuation | |
|---|---|
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.64 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | 393520.000 |
